Stratification of biologic use and outcomes within Age-of-onset/sex clusters
Within our biologic (OMA+ MEPO) cohort, the female/early-onset cluster was most prevalent, while the male/early-onset group was the least. Although biologic use across these phenotypes (Table 4) was significantly different, there was no statistically significant difference in response for either biologic across these phenotypes.